Evidence map›Paper›PMID 39109927›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2024

Cloning and Functional Characterization of Novel Human Neutralizing Anti-IFN-α and Anti-IFN-β Antibodies.

Emmanouil Papasavvas, Lily Lu, Matthew Fair, Isabela Oliva, Joel Cassel, Sonali Majumdar, Karam Mounzer, Jay R Kostman, Pablo Tebas, Amit Bar-Or and 2 more

Abstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Emmanouil PapasavvasThe Wistar Institute, Philadelphia, PA.
Lily LuThe Wistar Institute, Philadelphia, PA.
Matthew FairThe Wistar Institute, Philadelphia, PA.
Isabela OlivaThe Wistar Institute, Philadelphia, PA.ORCID 0009-0008-2328-062X
Joel CasselThe Wistar Institute, Philadelphia, PA.
Sonali MajumdarThe Wistar Institute, Philadelphia, PA.
Karam MounzerJonathan Lax Immune Disorders Treatment Center, Philadelphia Field Initiating Group for HIV-1 Trials, Philadelphia, PA.ORCID 0000-0001-8537-7103
Jay R KostmanJonathan Lax Immune Disorders Treatment Center, Philadelphia Field Initiating Group for HIV-1 Trials, Philadelphia, PA.
Pablo TebasDepartment of Medicine, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA.
Amit Bar-OrDepartment of Neurology and Center for Neuroinflammation and Experimental Therapeutics, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0001-7179-0335
Kar MuthumaniThe Wistar Institute, Philadelphia, PA.ORCID 0000-0002-6807-2065
Luis J MontanerThe Wistar Institute, Philadelphia, PA.ORCID 0000-0001-5799-6759

Funding

Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9M
BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination ImmunotherapyUM1AI164570 · NIAID · WISTAR INSTITUTE · PI Luis J Montaner, James L. Riley · 2021 to 2026
$34.7M
Herbert Kean, M.D., Family ProfessorshipNCI NIH HHS P30 CA010815NIAID NIH HHS UM1 AI164570The Robert I. Jacobs Fund of the Philadelphia FoundationWistar Cancer Center Grant P30 CA10815
6 · The paper itself

Abstract

Type I IFNs play a pivotal role in immune response modulation, yet dysregulation is implicated in various disorders. Therefore, it is crucial to develop tools that facilitate the understanding of their mechanism of action and enable the development of more effective anti-IFN therapeutic strategies. In this study, we isolated, cloned, and characterized anti-IFN-α and anti-IFN-β Abs from PBMCs of individuals treated with IFN-α or IFN-β, harboring confirmed neutralizing Abs. Clones AH07856 and AH07857 were identified as neutralizing anti-IFN-α-specific with inhibition against IFN-α2a, -α2b, and -αK subtypes. Clones AH07859 and AH07866 were identified as neutralizing anti-IFN-β1a-specific signaling and able to block lipopolysaccharide or S100 calcium-binding protein A14-induced IFN-β signaling effects. Cloned Abs bind rhesus but not murine IFNs. The specificity of inhibition between IFN-α and IFN-β suggests potential for diverse research and clinical applications.

Indexed as

Antibodies, NeutralizingCloning, MolecularInterferon-alphaInterferon-betaAnimalsHumansLeukocytes, MononuclearMiceSignal TransductionAntibodies, NeutralizingInterferon-alphaInterferon-beta

Identifiers

PMID39109927
PMCPMC11575944

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.